Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2023-08-30 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于参加2023年度天津辖区上市公司半年报业绩说明会暨投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in a 2023 half-year performance explanation meeting and an online investor reception day. It mentions the event date, participants, and how investors can interact, but does not contain any actual financial statements or detailed financial data. The document length is short (794 characters), and it serves as a notice of an upcoming event related to the half-year report rather than the report itself. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) as a general announcement about investor relations activities.
2023-08-30 Chinese
天士力关于获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding the receipt of a drug clinical trial approval notice from the National Medical Products Administration. It details the drug's basic information, development background, and risk warnings. The document is short (1490 characters) and serves as an official announcement of regulatory approval rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed report content. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-08-27 Chinese
天士力第八届董事会第21次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a board meeting resolution announcement from TianShiLi Pharmaceutical Group Co., Ltd. It details the resolutions passed at the 21st meeting of the 8th board, including approval of the 2023 semi-annual report, but does not contain the report itself. It references the full semi-annual report being published on the Shanghai Stock Exchange website. The document is short (987 characters) and serves as an announcement of board decisions and references other announcements for detailed information. This fits the category of Regulatory Filings (RNS) as it is a general regulatory announcement and does not contain substantive financial data or the full report itself.
2023-08-25 Chinese
天士力2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2023年半年度报告摘要" which translates to "2023 Semi-Annual Report Summary". It contains detailed financial data for the half-year period, including revenue, net profit, assets, and earnings per share. It also includes extensive management discussion and analysis of business operations, R&D progress, marketing strategies, and future plans. The document is about 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The content matches the characteristics of an Interim / Quarterly Report, providing comprehensive financial statements and business analysis for a period shorter than a full fiscal year (half-year). Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2023
2023-08-25 Chinese
天士力关于授权公司管理层处置部分交易性金融资产的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the board of directors of TianShiLi Pharmaceutical Group Co., Ltd. regarding the authorization for company management to dispose of certain trading financial assets, specifically shares of Keji Pharmaceutical Holdings Limited. It details the board meeting resolution, the nature of the transaction, the financial background of the target shares, and the authorization scope. The document is a formal announcement about a capital/financing activity (disposal of financial assets) rather than a full financial report or earnings release. It does not contain comprehensive financial statements or detailed financial analysis but focuses on the authorization and plan for asset disposal. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2446 characters, which is consistent with an announcement rather than a full report.
2023-08-25 Chinese
天士力2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2023 年半年度报告" which translates to "2023 Semi-Annual Report". It contains detailed financial data, management discussion and analysis, company overview, risk disclosures, and operational details for the first half of 2023. The length is substantial (15,000 characters), and it includes actual financial statements and substantive financial analysis. The content matches the characteristics of an Interim / Quarterly Report, which is a comprehensive financial report for a period shorter than a full fiscal year. It is not merely an announcement or a certification, but a full report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2023
2023-08-25 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.